Page 946 - Read Online

Caron de Fromentel et al. Hepatoma Res 2020;6:80 I http://dx.doi.org/10.20517/2394-5079.2020.77 Page 15 of 18

association with transcription factor ERCC3. Proc Natl Acad Sci U S A 1994;91:2230-4.
67. Levine AJ. The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene
products: p53. Virology 2009;384:285-93.
68. Sanz G, Singh M, Peuget S, Selivanova G. Inhibition of p53 inhibitors: progress, challenges and perspectives. J Mol Cell Biol
2019;11:586-99.
69. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
70. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res
1994;54:794-9.
71. Endo K, Ueda T, Ohta T, Terada T. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular
carcinoma. Liver 2000;20:209-15.
72. Bang S, Kaur S, Kurokawa M. Regulation of the p53 family proteins by the ubiquitin proteasomal pathway. Int J Mol Sci 2019;21:261.
73. Huang X, Qian X, Cheng C, et al. Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with
p27(Kip1) and cell proliferation. Hum Pathol 2011;42:507-15.
74. Lee YH, Andersen JB, Song HT, et al. Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular
carcinoma. Cancer Res 2010;70:8264-9.
75. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003;112:779-91.
76. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004;429:86-92.
77. Shen J, Li P, Shao X, et al. The E3 ligase RING1 targets p53 for degradation and promotes cancer cell proliferation and survival. Cancer
Res 2018;78:359-71.
78. Pan Y, Wang B, Yang X, et al. CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal
transition. Sci Rep 2015;5:17006.
79. Zhu K, Li J, Li J, et al. Ring1 promotes the transformation of hepatic progenitor cells into cancer stem cells through the Wnt/β-catenin
signaling pathway. J Cell Biochem 2019;Online ahead of print.
80. Gao J, Buckley SM, Cimmino L, et al. The CUL4-DDB1 ubiquitin ligase complex controls adult and embryonic stem cell differentiation
and homeostasis. Elife 2015;4:e07539.
81. Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets
Ther 2013;7:57-68.
82. Davison TS, Vagner C, Kaghad M, et al. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not
with p53. J Biol Chem 1999;274:18709-14.
83. Irwin M, Marin MC, Phillips AC, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000;407:645-8.
84. Seelan RS, Irwin M, van der Stoop P, et al. The human p73 promoter: characterization and identification of functional E2F binding sites.
Neoplasia 2002;4:195-203.
85. Stiewe T, Pützer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000;26:464-9.
86. Costanzo A, Merlo P, Pediconi N, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target
genes. Molecular Cell 2002;9:175-86.
87. Pediconi N, Ianari A, Costanzo A, et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol
2003;5:552-8.
88. Pediconi N, Guerrieri F, Vossio S, et al. hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA
damage. Mol Cell Biol 2009;29:1989-98.
89. Marabese M, Vikhanskaya F, Rainelli C, Sakai T, Broggini M. DNA damage induces transcriptional activation of p73 by removing
C-EBPalpha repression on E2F1. Nucleic Acids Res 2003;31:6624-32.
90. Fontemaggi G, Gurtner A, Strano S, et al. The transcriptional repressor ZEB regulates p73 expression at the crossroad between
proliferation and differentiation. Mol Cell Biol 2001;21:8461-70.
91. Wu S, Murai S, Kataoka K, Miyagishi M. Yin Yang 1 induces transcriptional activity of p73 through cooperation with E2F1. Biochem
Biophys Res Commun 2008;365:75-81.
92. Grob TJ, Novak U, Maisse C, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death
Differ 2001;8:1213-23.
93. Vossio S, Palescandolo E, Pediconi N, et al. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced
cell cycle arrest. Oncogene 2002;21:3796-803.
94. Kartasheva NN, Contente A, Lenz-Stöppler C, Roth J, Dobbelstein M. p53 induces the expression of its antagonist p73 Delta N,
establishing an autoregulatory feedback loop. Oncogene 2002;21:4715-27.
95. Nakagawa T, Takahashi M, Ozaki T, et al. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a
p73-specific target element within the Delta Np73 promoter. Mol Cell Biol 2002;22:2575-85.
96. Lunghi P, Costanzo A, Mazzera L, et al. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting.
Clin Cancer Res 2009;15:6495-502.
97. Irwin MS, Kondo K, Marin MC, et al. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403-10.
98. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically
defined subset of primary breast cancers. J Clin Invest 2007;117:1370-80.
99. Ishimoto O, Kawahara C, Enjo K, et al. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res
2002;62:636-41.